EpCAM+ Progenitor Cell Sorting for Hepatic Organoid Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating three-dimensional liver organoids from induced pluripotent stem cells are costly, time-consuming, and reliant on commercial media, with limited longevity and heterogeneity in cellular populations, leading to inconsistent liver functionality.
Innovation Solution
The development of a method using EpCAM+ endodermal progenitor cells for the differentiation of induced pluripotent stem cells into functional hepatic organoids, which can be cultured for over a year, achieves specific liver functions like albumin production and glycogen storage, and is independent of commercial media, utilizing a homogenous cell population for efficient organoid formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to generate liver organoids from induced pluripotent stem cells, then organoid formation can be achieved, but the process is time-consuming (taking up to 68 days) and costly due to dependency on commercial media
Solution Approach 1:
The patent applies preliminary action by pre-differentiating induced pluripotent stem cells into EpCAM+ endodermal progenitor cells before organoid formation. This pre-preparation of specific progenitor cells accelerates the overall process, reducing organoid formation time from 68 days to 14 days while maintaining functionality.
Solution Approach 2:
The patent changes key parameters by replacing commercial HCM medium with a defined culture medium containing specific growth factors (EGF, FGF10, HGF, gastrin, RSPO1, Noggin, Y27632) at optimized concentrations. This parameter optimization enables faster organoid formation and eliminates dependency on proprietary commercial media.
2Ease of manufacture
If conventional organoid culture methods are used, then organoids can be formed, but they rely on expensive commercial media with unknown component amounts and lack alternatives
Solution Approach 1:
The patent replaces expensive, proprietary commercial HCM medium with a cost-effective, defined culture medium formulation. The new medium uses individually purchased growth factors at known concentrations, eliminating the need for expensive commercial products while maintaining organoid viability and functionality.
Solution Approach 2:
The patent defines exact concentrations of all medium components (EGF 50 ng/mL, FGF10 100 ng/mL, HGF 25 ng/mL, gastrin 10 nM, RSPO1 10%, Noggin 25 ng/mL, Y27632 10 μM) to replace commercial media. This parameter specification enables cost reduction while ensuring reproducibility and eliminating dependency on proprietary formulations.
3Reliability
If heterogeneous cell populations are used for organoid formation, then organoid structure can be established, but cellular content and functionality in late passages remain unknown and inconsistent
Solution Approach 1:
The patent applies local quality by selecting and culturing only EpCAM+ endodermal progenitor cells with specific hepatogenic potential. This selective approach ensures homogeneous cell populations with consistent differentiation capacity, improving reliability of liver-specific functions (albumin production, glycogen storage, LDL uptake, CYP450 activity) in late passages.
Solution Approach 2:
The patent achieves homogeneity by using a defined culture medium that maintains uniform cell characteristics throughout culture. The optimized medium composition ensures all cells receive identical growth signals, producing consistent cellular content and stable liver functionality even after prolonged culture periods.
4Productivity
If conventional protocols are used, then organoid formation can occur, but the process requires multiple steps (single cell formation, 3D spheroid structure, conversion back to single cell) that increase complexity and cost
Solution Approach 1:
The patent simplifies the process by performing preliminary differentiation of iPSCs into EpCAM+ endodermal progenitor cells before organoid formation. This pre-preparation eliminates the need for multiple conversion steps (single cell→3D spheroid→single cell), reducing procedural complexity while maintaining organoid quality.
Data Source
AI summary
A three-dimensional (3D) liver organoid obtained through the differentiation of induced pluripotent stem cells (IPSCs) in laboratory culture medium and a production method of the 3D hepatic organoid are provided. The production method includes the following steps: differentiating the IPSCs into a definitive endoderm in a medium containing Activin A, Wnt3a, and R-spo1 factors; adding 5 ng/ml R-spo 1 during IPSC differentiation to increase an amount of EpCAM+endoderm progenitor cells; cell sorting of the EpCAM+endoderm progenitor cells through a fluorescence-activated cell sorting (FACS) method; culturing a sorted EpCAM+endoderm progenitor cells in a 3D Matrigel medium of 37° C., 5% CO2, 95% humidity and 7.2-7.5 pH.